Nick Kinney1, Timothy R Larsen2, David M Kim2, Robin T Varghese1, Steven Poelzing3, Harold R Garner1,4, Soufian T AlMahameed2,5. 1. Edward Via College of Osteopathic Medicine, Blacksburg, Virginia. 2. Carilion Clinic and Virginia Tech Carilion School of Medicine, Roanoke, Virginia. 3. Virginia Tech Carilion Research Institute, and the Center for Heart and Regenerative Medicine, Virginia Polytechnic University, Roanoke, Virginia. 4. Gibbs Cancer Center and Research Institute, Spartanburg, South Carolina. 5. MetroHealth Medical Center and Case Western Reserve University, Cleveland, Ohio.
Abstract
BACKGROUND: Dofetilide is a class III antiarrhythmic drug effective for the treatment of atrial fibrillation (AF). Dofetilide initiation (DI) associates with corrected QT interval (QTc) prolongation. Significant QTc prolongation during DI mandates dose adjustment or discontinuation of the drug. Microsatellite DNA are novel genetic markers associated with congenital and acquired health conditions. HYPOTHESIS: DNA microsatellite polymorphism may associate with QTc response to dofetilide initiation in patients with persistent AF. METHODS: We performed whole-exome sequencing in a cohort of patients with persistent AF undergoing DI. Electrocardiographic variables and clinical data were assessed. We defined patients as eligible for DI when no significant QTc prolongation (>20% compared with baseline) was seen with a 500-μg dose. We defined patients as ineligible for DI when significant QTc prolongation was seen during DI with 500 μg. We investigated polymorphisms for 11 919 DNA microsatellite loci in relation to QTc response to DI. RESULTS: During the study, 14 consecutive patients with persistent AF presenting for DI were enrolled. Whole-exome sequencing revealed 14 different microsatellite loci in the 2 groups. All genes or proximal genes that harbor these loci are known to have expression in the human heart. Two genes, MYH6 and TRAK2, are known to have expression in the atria. TRAK2 is known to interact with KCNJ2, the inward-rectifier potassium channel 1. CONCLUSIONS: Microsatellite DNA polymorphisms seem to associate with QTc response to DI therapy in patients with persistent AF who are deemed otherwise eligible for dofetilide therapy.
BACKGROUND:Dofetilide is a class III antiarrhythmic drug effective for the treatment of atrial fibrillation (AF). Dofetilide initiation (DI) associates with corrected QT interval (QTc) prolongation. Significant QTc prolongation during DI mandates dose adjustment or discontinuation of the drug. Microsatellite DNA are novel genetic markers associated with congenital and acquired health conditions. HYPOTHESIS: DNA microsatellite polymorphism may associate with QTc response to dofetilide initiation in patients with persistent AF. METHODS: We performed whole-exome sequencing in a cohort of patients with persistent AF undergoing DI. Electrocardiographic variables and clinical data were assessed. We defined patients as eligible for DI when no significant QTc prolongation (>20% compared with baseline) was seen with a 500-μg dose. We defined patients as ineligible for DI when significant QTc prolongation was seen during DI with 500 μg. We investigated polymorphisms for 11 919 DNA microsatellite loci in relation to QTc response to DI. RESULTS: During the study, 14 consecutive patients with persistent AF presenting for DI were enrolled. Whole-exome sequencing revealed 14 different microsatellite loci in the 2 groups. All genes or proximal genes that harbor these loci are known to have expression in the human heart. Two genes, MYH6 and TRAK2, are known to have expression in the atria. TRAK2 is known to interact with KCNJ2, the inward-rectifier potassium channel 1. CONCLUSIONS: Microsatellite DNA polymorphisms seem to associate with QTc response to DI therapy in patients with persistent AF who are deemed otherwise eligible for dofetilide therapy.
Authors: D C Rubinsztein; J Leggo; R Coles; E Almqvist; V Biancalana; J J Cassiman; K Chotai; M Connarty; D Crauford; A Curtis; D Curtis; M J Davidson; A M Differ; C Dode; A Dodge; M Frontali; N G Ranen; O C Stine; M Sherr; M H Abbott; M L Franz; C A Graham; P S Harper; J C Hedreen; M R Hayden Journal: Am J Hum Genet Date: 1996-07 Impact factor: 11.025
Authors: C Torp-Pedersen; M Møller; P E Bloch-Thomsen; L Køber; E Sandøe; K Egstrup; E Agner; J Carlsen; J Videbaek; B Marchant; A J Camm Journal: N Engl J Med Date: 1999-09-16 Impact factor: 91.245
Authors: Jonathan S L Earle; Rajyalakshmi Luthra; Angela Romans; Ronald Abraham; Joe Ensor; Hui Yao; Stanley R Hamilton Journal: J Mol Diagn Date: 2010-04-22 Impact factor: 5.568
Authors: Daniel F Gudbjartsson; David O Arnar; Anna Helgadottir; Solveig Gretarsdottir; Hilma Holm; Asgeir Sigurdsson; Adalbjorg Jonasdottir; Adam Baker; Gudmar Thorleifsson; Kristleifur Kristjansson; Arnar Palsson; Thorarinn Blondal; Patrick Sulem; Valgerdur M Backman; Gudmundur A Hardarson; Ebba Palsdottir; Agnar Helgason; Runa Sigurjonsdottir; Jon T Sverrisson; Konstantinos Kostulas; Maggie C Y Ng; Larry Baum; Wing Yee So; Ka Sing Wong; Juliana C N Chan; Karen L Furie; Steven M Greenberg; Michelle Sale; Peter Kelly; Calum A MacRae; Eric E Smith; Jonathan Rosand; Jan Hillert; Ronald C W Ma; Patrick T Ellinor; Gudmundur Thorgeirsson; Jeffrey R Gulcher; Augustine Kong; Unnur Thorsteinsdottir; Kari Stefansson Journal: Nature Date: 2007-07-01 Impact factor: 49.962
Authors: Nick Kinney; Timothy R Larsen; David M Kim; Robin T Varghese; Steven Poelzing; Harold R Garner; Soufian T AlMahameed Journal: Clin Cardiol Date: 2018-06-11 Impact factor: 2.882